Works matching IS 09024441 AND DT 2024 AND VI 112 AND IP 3
Results: 21
Featured Cover.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. i, doi. 10.1111/ejh.14190
- By:
- Publication type:
- Article
Hydroxyurea at escalated dose versus fixed low‐dose hydroxyurea in adults with sickle cell disease.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 466, doi. 10.1111/ejh.14138
- By:
- Publication type:
- Article
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 458, doi. 10.1111/ejh.14137
- By:
- Publication type:
- Article
Complement‐mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 450, doi. 10.1111/ejh.14136
- By:
- Publication type:
- Article
The current challenges faced by people with hemophilia B.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 339, doi. 10.1111/ejh.14135
- By:
- Publication type:
- Article
DNMTs‐mediated SOCS3 methylation promotes the occurrence and development of AML.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 439, doi. 10.1111/ejh.14134
- By:
- Publication type:
- Article
Late‐onset Pneumocystis jirovecii pneumonia post‐allogeneic stem cell transplantation after time‐dependent discontinuation of prophylaxis.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 433, doi. 10.1111/ejh.14133
- By:
- Publication type:
- Article
Real‐world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 424, doi. 10.1111/ejh.14131
- By:
- Publication type:
- Article
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 479, doi. 10.1111/ejh.14130
- Publication type:
- Article
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 328, doi. 10.1111/ejh.14129
- By:
- Publication type:
- Article
The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 412, doi. 10.1111/ejh.14128
- By:
- Publication type:
- Article
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 402, doi. 10.1111/ejh.14127
- By:
- Publication type:
- Article
Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 392, doi. 10.1111/ejh.14125
- By:
- Publication type:
- Article
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 379, doi. 10.1111/ejh.14124
- By:
- Publication type:
- Article
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 371, doi. 10.1111/ejh.14122
- By:
- Publication type:
- Article
Teclistamab‐cqyv in multiple myeloma.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 320, doi. 10.1111/ejh.14121
- By:
- Publication type:
- Article
Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 367, doi. 10.1111/ejh.14120
- By:
- Publication type:
- Article
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 350, doi. 10.1111/ejh.14118
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 317, doi. 10.1111/ejh.13996
- Publication type:
- Article
Treatment sequences and drug costs from diagnosis to death in multiple myeloma.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 360, doi. 10.1111/ejh.14119
- By:
- Publication type:
- Article